Clinical trials: Tenecteplase
THROMBOLYSIS
Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
This study will evaluate the efficacy and safety of tenecteplase compared with placebo in participants with acute ischemic stroke (AIS).
- Trial name
- TIMELESS (NCT03785678)
- Testing
- Tenecteplase
- Where
- 97 sites in United States, Canada
- Volunteers
- 458 people
- Sponsor
- Genentech, Inc.
Dysfunctional Hemodialysis Catheters
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters
This was a Phase III, randomized, double-blind, placebo-controlled study conducted at 37 centers in the United States. 150 subjects ≥ 16 years of age who required hemodialysis (HD) and had a dysfunctional HD catheter were…
- Trial name
- TROPICS 3 (NCT00396032)
- Testing
- tenecteplase
- Volunteers
- 150 people
- Sponsor
- Genentech, Inc.
Dysfunctional Central Venous Access Catheters
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
This was a Phase III, open-label, single-arm study that was conducted at 43 centers in the United States and Canada. 251 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were enrolled in the study…
- Trial name
- TROPICS 2 (NCT00396318)
- Testing
- tenecteplase
- Volunteers
- 251 people
- Sponsor
- Genentech, Inc.
Dysfunctional Central Venous Access Catheters
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
This was a Phase III, randomized, double-blind, placebo-controlled study that was conducted at 24 centers in the United States and Canada.
- Trial name
- TROPICS 1 (NCT00395876)
- Testing
- tenecteplase
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Dysfunctional Hemodialysis Catheters
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
This was a Phase III, open-label study conducted at 44 centers in the United States, Canada, and Puerto Rico. 223 subjects who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.
- Trial name
- TROPICS 4 (NCT00396253)
- Testing
- Tenecteplase
- Volunteers
- 223 people
- Sponsor
- Genentech, Inc.
Myocardial Infarction
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients presenting ST-segment elevation myocardial infarction in comparison to…
- Trial name
- FRIDOM1 (NCT02301910)
- Testing
- Recombinant staphylokinase, Tenecteplase
- Where
- 17 sites in Russia
- Volunteers
- 382 people
- Sponsor
- Supergene, LLC
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30…
- Trial name
- ORIGINAL (NCT04915729)
- Testing
- tenecteplase, alteplase
- Where
- 55 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim